SYNERGY: Custirsen in Poor-Prognosis mCRPC

May 29-June 2, 2015; Chicago, Illinois
A retrospective exploratory analysis of the phase III SYNERGY trial shows that adding custirsen to docetaxel/prednisone selectively improves survival in treatment-naive patients with mCRPC and a poor prognosis.
Format: Microsoft PowerPoint (.ppt)
File Size: 452 KB
Released: June 5, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

Review key clinical data in prostate cancer and urothelial carcinoma from ASCO 2019 with this expert analysis from Daniel P. Petrylak, MD

Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 16, 2019 Expiration: August 15, 2020

Drs. Todd M. Bauer, Giuseppe Giaccone, Axel Grothey, John L. Marshall, and Michael J. Pishvaian discuss the latest data on 10 key clinical biomarkers in solid tumors.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Giuseppe Giaccone, MD, PhD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 11, 2019 Expiration: July 10, 2020

Phase III TITAN trial of apalutamide + ADT for patients with metastatic castration-sensitive prostate cancer, as reported by CCO from ASCO 2019.

Released: June 7, 2019

Results from the phase III ENZAMET trial of enzalutamide in metastatic hormone-sensitive prostate cancer as reported by CCO from ASCO 2019

Released: June 6, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?